Study Results Find Interaction Between Fedratinib and a Strong Inhibitor of CYP3A4
Fedratinib, a selective inhibitor of JAK2, was approved in 2019 by the US FDA for the treatment of certain groups of patients with myelofibrosis.
Myelofibrosis
Management of Patients With Myelofibrosis Experiencing Ruxolitinib Failure
Identification of the underlying pattern for ruxolitinib failure in patients with myelofibrosis is a significant factor in determining appropriate treatment.
Second Cancers Pose Significant Mortality Risk in Myeloproliferative Neoplasms
Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.
Ruxolitinib May Be Effective for Reducing Spleen Length in Patients With Myelofibrosis
By week 24 of the study, a reduction in palpable spleen length of at least 50% was reported in more than half of patients who underwent splenomegaly.
Why Do Patients With Myelofibrosis Discontinue Ruxolitinib?
Researchers assessed how the reasons that led to discontinuation of ruxolitinib influenced survival in patients with myelofibrosis.
Ruxolitinib Plus PEG-IFNα2 for Patients With Polycythemia Vera or Myelofibrosis
The study’s primary endpoint was efficacy, determined by complete remission, peripheral blood cell count remission, quality of life, and JAK2 V617F allele burden.
Clinical Relevance of Key Genetic Mutations in Primary and Secondary Myelofibrosis
Researchers assessed patterns of genetic mutations and their prognostic effects in patients with primary and secondary myelofibrosis.
New Treatment Option Approved for Patients With Myelofibrosis
The FDA has approved Inrebic (fedratinib; Celgene) capsules to treat adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
Response to Iron Chelation Therapy May Predict Improvement in Transfusion-Dependent Myelofibrosis
Patients who experienced an iron chelation response had lower transfusion burden and substantial decrease in ferritin values.
Ruxolitinib Plus Azacitidine May Benefit Patients With Myelofibrosis
The combination of the 2 drugs seems to display synergistic effects.
Next post in General Hematology
